Mani Foroohar
Stock Analyst at Leerink Partners
(2.27)
# 2,749
Out of 4,984 analysts
167
Total ratings
49.45%
Success rate
-5.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Underperform | $18 → $15 | $24.84 | -39.61% | 18 | Aug 22, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $18.10 | -44.75% | 2 | Jul 21, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $3.25 | +146.15% | 12 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $5.21 | +245.49% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.84 | +23.97% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $6.69 | +303.59% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $17.44 | +312.84% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $2.77 | +513.72% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $73.79 | -33.60% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $51.49 | -10.66% | 15 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $6.82 | +222.58% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $61.32 | +1.12% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $13.88 | -6.34% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $19.11 | +51.75% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.35 | -25.23% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.26 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $6.07 | +411.13% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.26 | +455.56% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $29.42 | +35.96% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $12.27 | +584.60% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.83 | +147.35% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $22.91 | +236.10% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $461.24 | -69.00% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.68 | +5.63% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $61.19 | +24.20% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.80 | +1,788.89% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $3.02 | +562.25% | 6 | Jul 23, 2021 |
Moderna
Aug 22, 2025
Maintains: Underperform
Price Target: $18 → $15
Current: $24.84
Upside: -39.61%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $18.10
Upside: -44.75%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $3.25
Upside: +146.15%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $5.21
Upside: +245.49%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.84
Upside: +23.97%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $6.69
Upside: +303.59%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $17.44
Upside: +312.84%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $2.77
Upside: +513.72%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $73.79
Upside: -33.60%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $51.49
Upside: -10.66%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.82
Upside: +222.58%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $61.32
Upside: +1.12%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $13.88
Upside: -6.34%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $19.11
Upside: +51.75%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.35
Upside: -25.23%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $9.26
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $6.07
Upside: +411.13%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $1.26
Upside: +455.56%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $29.42
Upside: +35.96%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $12.27
Upside: +584.60%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.83
Upside: +147.35%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $22.91
Upside: +236.10%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $461.24
Upside: -69.00%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.68
Upside: +5.63%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $61.19
Upside: +24.20%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.80
Upside: +1,788.89%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $3.02
Upside: +562.25%